Cirrhosis News and Research

Latest Cirrhosis News and Research

Antiviral therapy cuts progression to cancer in hepatitis

Antiviral therapy may prevent the most common form of liver cancer developing among patients who have hepatitis C-related fibrosis or cirrhosis, report researchers.

25 Oct 2012

Statins could be first preventive treatment for liver cancer

Statins may reduce the risk for hepatocellular carcinoma, show the results of a meta-analysis.

15 Oct 2012

Scientists look to use natural killer cells to target common form of liver cancer

Scientists at the University of Southampton are to investigate the best way to use natural killer cells (NK) to target the most common form of liver cancer. NK cells are able to directly kill cancer in the body and stimulate other cells in the immune system to help attack cancer.

14 Oct 2012

Researchers discover mechanism by which magnesium reduces cytokine production

Magnesium sulfate is given to many pregnant women to treat preterm labor and preeclampsia and was recently shown to prevent cerebral palsy; however little is known about how it works. Researchers at Case Western Reserve University School of Medicine recently discovered the mechanism by which magnesium reduces the production of cytokines.

10 Oct 2012

Researchers decipher how AP-1 gene regulator controls survival of liver tumor-initiating cells

Researchers headed by Erwin Wagner, the Director of the BBVA Foundation-CNIO Cancer Cell Biology Programme at the Spanish National Cancer Research Centre (CNIO), have deciphered how a stress-inducible gene regulator, AP-1, controls the survival of liver tumor-initiating cells. These results, published in the online edition of Nature Cell Biology, could provide new preventive strategies and identify potentially targetable molecules to prevent liver cancer.

8 Oct 2012

New nanodevice lays foundations for future development of novel therapies against aging

A team of Spanish scientists has developed an intelligent nanodevice that lays the foundations for the future development of new therapies against aging. The device consists of nanoparticles that can selectively release drugs in aged human cells.

4 Oct 2012

Prognosis still poor for EVB in cirrhosis

The current standard of care for esophageal variceal bleeding in liver cirrhosis is very effective at controlling bleeding but patient prognosis remains poor, say the authors of an Italian study.

1 Oct 2012

Thymus tissue, iPSCS and liver cells can thrive in lymph nodes

Lymph nodes can provide a suitable home for a variety of cells and tissues from other organs, suggesting that a cell-based alternative to whole organ transplantation might one day be feasible, according to researchers at the University of Pittsburgh School of Medicine and its McGowan Institute for Regenerative Medicine.

28 Sep 2012

Incarcerated patients with chronic HCV likely to achieve sustained viral response

Incarcerated patients with chronic hepatitis C virus (HCV) infection are just as likely to respond to treatment for the disease as patients in the community, according to findings published in the October issue of Hepatology, a peer-reviewed journal of the American Association for the Study of Liver Diseases.

28 Sep 2012

Dietary habits associated with NAFLD in obese children

Research has identified a number of variables associated with nonalcoholic fatty liver disease in obese children.

27 Sep 2012

Postsurgery mortality rates vary across Europe

Europe-wide data suggest that mortality rates after noncardiac surgery are higher than expected, and vary substantially by country, reports an international research team in The Lancet.

27 Sep 2012

PPI use linked with risk for infection in decompensated cirrhosis

Proton-pump inhibitors are associated with an increased risk for serious infections in patients with decompensated cirrhosis, research shows.

24 Sep 2012

UMDNJ, Proteonomix to conduct UMK-121 Phase 1 trial in end-stage liver disease

Proteonomix, Inc., a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, today announced it has entered into an agreement with Piscataway, N.J.-based University of Medicine and Dentistry of New Jersey (UMDNJ) to conducted a Phase 1 clinical trial with its proprietary, patent-pending mobilization technology UMK-121 in patients with end-stage liver disease (ESLD).

15 Sep 2012

Researchers identify three genetic regions associated with primary biliary cirrhosis

Researchers have newly identified three genetic regions associated with primary biliary cirrhosis (PBC), the most common autoimmune liver disease, increasing the number of known regions associated with the disorder to 25.

10 Sep 2012

GSK, University of Cambridge aim to discover and develop new medicines for liver disease

A new collaboration based at the University of Cambridge will aim to discover and develop new medicines to treat liver disease.

10 Sep 2012

Children and young patients with chronic HBV infection do have a protective immune response

Scientists from A*STAR's Singapore Institute for Clinical Sciences (SICS), together with clinical collaborators from London , discovered for the first time that children and young patients with chronic Hepatitis B Virus infection (HBV carriers) do have a protective immune response, contrary to current belief, and hence can be more suitable treatment candidates than previously considered.

7 Sep 2012

Telaprevir offers advantages in patients with chronic hepatitis C infection of genotype 1

The drug telaprevir has been available for treatment of chronic hepatitis C infection of genotype 1 since autumn 2011. In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether telaprevir offers an added benefit compared with the present standard therapy.

6 Sep 2012

NCI awards Soligenix $300,000 SBIR grant for orBec Phase 2 chronic GI GVHD trial

Soligenix, Inc., a development stage biopharmaceutical company, announced today that the National Cancer Institute has awarded Soligenix a Small Business Innovation Research grant to support the conduct of a Phase 2 clinical trial designed to evaluate orBec (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal manifestation of chronic Graft-versus-Host disease.

5 Sep 2012

Southampton Traffic Light test could easily diagnose liver fibrosis and cirrhosis

A new 'traffic light' test devised by Dr Nick Sheron and colleagues at University of Southampton and Southampton General Hospital could be used in primary care to diagnose liver fibrosis and cirrhosis in high risk populations more easily than at present.

30 Aug 2012

Corporate power presents a major threat to public health

Professor Gerard Hastings from the Institute for Social Marketing at the University of Stirling argues that marketing by multinational corporations "threatens our mental wellbeing, exacerbates inequalities, and encourages unsustainable consumption."

22 Aug 2012

Cirrhosis News and Research

Latest Cirrhosis News and Research

Antiviral therapy cuts progression to cancer in hepatitis

Statins could be first preventive treatment for liver cancer

Scientists look to use natural killer cells to target common form of liver cancer

Researchers discover mechanism by which magnesium reduces cytokine production

Researchers decipher how AP-1 gene regulator controls survival of liver tumor-initiating cells

New nanodevice lays foundations for future development of novel therapies against aging

Prognosis still poor for EVB in cirrhosis

Thymus tissue, iPSCS and liver cells can thrive in lymph nodes

Incarcerated patients with chronic HCV likely to achieve sustained viral response

Dietary habits associated with NAFLD in obese children

Postsurgery mortality rates vary across Europe

PPI use linked with risk for infection in decompensated cirrhosis

UMDNJ, Proteonomix to conduct UMK-121 Phase 1 trial in end-stage liver disease

Researchers identify three genetic regions associated with primary biliary cirrhosis

GSK, University of Cambridge aim to discover and develop new medicines for liver disease

Children and young patients with chronic HBV infection do have a protective immune response

Telaprevir offers advantages in patients with chronic hepatitis C infection of genotype 1

NCI awards Soligenix $300,000 SBIR grant for orBec Phase 2 chronic GI GVHD trial

Southampton Traffic Light test could easily diagnose liver fibrosis and cirrhosis

Corporate power presents a major threat to public health

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Cirrhosis News and Research

Latest Cirrhosis News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in